|  |
| --- |
| **Supplemental Table 1. Additional Baseline Characteristic and PrEP medication levels for PrEP Demonstration Project Participants by Retention Category** |
|  | **Complete Retention** |  | **ELTF** |  | **Intermittent Retention** |  | **Total** |
| **Characteristic** | Count/ | Row % |  | Count/ | Row% |  | Count/ | Row % |  | Count/ | Col % |
|   |   |  |  |  |  |  |  |  |  |  |  |  |
| Current living situation |  |  |  |  |  |  |  |  |  |  |  |
|  | Own/rent living space | 314 | 70.7% |  | 38 | 8.6% |  | 92 | 20.7% |  | 444 | 80.1% |
|   | Other | 52 | 47.3% |  | 23 | 20.9% |  | 35 | 31.8% |  | 110 | 19.9% |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Alcohol use |  |  |  |  |  |  |  |  |  |  |  |
|   | Light drinker | 165 | 66.3% |  | 26 | 10.4% |  | 58 | 23.3% |  | 249 | 44.9% |
| Intermediate drinker | 124 | 66.0% |  | 16 | 8.5% |  | 48 | 25.5% |  | 188 | 33.9% |
| Heavy Drinker | 77 | 65.8% |  | 19 | 16.2% |  | 21 | 17.9% |  | 117 | 21.1% |
| Marijuana use | 158 | 64.8% |  | 30 | 12.3% |  | 56 | 23.0% |  | 244 | 44.0% |
| Inhalant use | 176 | 69.0% |  | 15 | 5.9% |  | 64 | 25.1% |  | 255 | 46.0% |
| Cocaine use | 74 | 66.1% |  | 15 | 13.4% |  | 23 | 20.5% |  | 112 | 20.2% |
| Amphetamine use | 61 | 74.4% |  | 5 | 6.1% |  | 16 | 19.5% |  | 82 | 14.8% |
| Tranquilizer use | 18 | 75.0% |  | 2 | 8.3% |  | 4 | 16.7% |  | 24 | 4.3% |
| Club drug use | 86 | 67.7% |  | 13 | 10.2% |  | 28 | 22.0% |  | 127 | 22.9% |
| Hallucinogen use | 22 | 75.9% |  | 2 | 6.9% |  | 5 | 17.2% |  | 29 | 5.2% |
| ED drug use | 136 | 76.4% |  | 6 | 3.4% |  | 36 | 20.2% |  | 178 | 32.1% |
| Heroin use | 1 | 50.0% |  | 1 | 50.0% |  | 0 | 0.0% |  | 2 | 0.4% |
| Methadone use | 2 | 100.0% |  | 0 | 0.0% |  | 0 | 0.0% |  | 2 | 0.4% |
| Pain pill use | 9 | 81.8% |  | 0 | 0.0% |  | 2 | 18.2% |  | 11 | 2.0% |
| Injected drugs in last 3 months | 7 | 77.8% |  | 1 | 11.1% |  | 1 | 11.1% |  | 9 | 1.6% |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| Primary partner's HIV status |  |  |  |  |  |  |  |  |  |  |  |
|   | No main partner | 180 | 62.3% |  | 33 | 11.4% |  | 76 | 26.3% |  | 289 | 52.2% |
| HIV positive | 102 | 77.9% |  | 8 | 6.1% |  | 21 | 16.0% |  | 131 | 23.6% |
| HIV negative | 84 | 62.7% |  | 20 | 14.9% |  | 30 | 22.4% |  | 134 | 24.2% |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| Condomless receptive anal sex last 3 months |  |  |  |  |  |  |  |  |  |  |  |
| No | 107 | 58.8% |  | 25 | 13.7% |  | 50 | 27.5% |  | 182 | 32.9% |
| Yes | 259 | 69.6% |  | 36 | 9.7% |  | 77 | 20.7% |  | 372 | 67.1% |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| <2 HIV negative partner |  |  |  |  |  |  |  |  |  |  |  |
| No | 148 | 68.5% |  | 20 | 9.3% |  | 48 | 22.2% |  | 216 | 39.0% |
| Yes | 218 | 64.5% |  | 41 | 12.1% |  | 79 | 23.4% |  | 338 | 61.0% |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| <2 HIV positive partner |  |  |  |  |  |  |  |  |  |  |  |
| No | 96 | 71.6% |  | 4 | 3.0% |  | 34 | 25.4% |  | 134 | 24.2% |
| Yes | 270 | 64.3% |  | 57 | 13.6% |  | 93 | 22.1% |  | 420 | 75.8% |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| <2 HIV status unknown partner |  |  |  |  |  |  |  |  |  |  |  |
| No | 221 | 69.3% |  | 23 | 7.2% |  | 75 | 23.5% |  | 319 | 57.6% |
| Yes | 145 | 61.7% |  | 38 | 16.2% |  | 52 | 22.1% |  | 235 | 42.4% |
|  |  | Median | 25,75% |   | Median | 25,75% |   | Median | 25,75% |   | Median | 25,75% |
| # of male anal sex partners in 3 months | 5 | 3,12 |  | 3 | 1,6 |  | 5 | 3,10 |  | 5 | 2,10 |
| # of HIV negative or unknown status partners | 5 | 2,10 |  | 3 | 1,6 |  | 4 | 2,9 |  | 4 | 2,10 |
| # of condomless HIV positive partners | 1 | 0,2 |  | 0 | 0,1 |  | 1 | 0,2 |  | 1 | 0,1 |
| # of condomless HIV negative partners | 2 | 0,5 |  | 1 | 0,1 |  | 2 | 0,5 |  | 2 | 0,5 |
| # of condomless partners of unknown HIV status | 0 | 0,4 |  | 0 | 0,1 |  | 1 | 0,4 |  | 0 | 0,4 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| 4 Week DBS Measure |  |  |  |  |  |  |  |  |  |  |  |
|   | Missing | 175 | 66.3% |  | 40 | 15.2% |  | 49 | 18.6% |  | 267 | 47.9% |
| <2 doses | 5 | 21.7% |  | 10 | 43.5% |  | 8 | 34.8% |  | 23 | 4.1% |
| 2-3 doses | 12 | 44.4% |  | 1 | 3.7% |  | 14 | 51.9% |  | 27 | 4.8% |
| 4-6 doses | 83 | 71.6% |  | 9 | 7.8% |  | 24 | 20.7% |  | 116 | 20.8% |
| Daily | 91 | 73.4% |  | 1 | 0.8% |  | 32 | 25.8% |  | 124 | 22.3% |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| 12 Week DBS Measure |  |  |  |  |  |  |  |  |  |  |  |
|   | Missing | 58 | 41.1% |  | 56 | 41.8% |  | 27 | 19.1% |  | 144 | 25.9% |
| <2 doses | 8 | 25.8% |  | 0 | 0.0% |  | 19 | 61.3% |  | 31 | 5.6% |
| 2-3 doses | 20 | 52.6% |  | 0 | 0.0% |  | 17 | 44.7% |  | 38 | 6.8% |
| 4-6 doses | 119 | 75.8% |  | 0 | 0.0% |  | 38 | 24.2% |  | 157 | 28.2% |
| Daily | 161 | 86.1% |   | 0 | 0.0% |   | 26 | 13.9% |   | 187 | 33.6% |
|  | DBS=dried blood spot |  |  |  |  |